TriangleDISEASE & TREATMENT SETTING
KEYTRUDA QLEX: unresectable metastatic gastric cancer with HER2 positive, PD-L1 stated without a specific alteration (first-line)
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.8 Gastric Cancer KEYTRUDA QLEX, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
Broader topic: Gastric Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- first-line
- Stage
- Not part of this definition
- Resectability
- unresectable
Biomarkers, prior therapy and derivation
- molecular
- gene
- HER2
- alteration
- positive
- status
- present
- gene
- PD-L1
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for KEYTRUDA QLEX (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.8 Gastric Cancer KEYTRUDA QLEX, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
Study evidence for this setting
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarci
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice